董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Taylor Harris | 男 | Independent Director | 50 | 20.10万美元 | 未持股 | 2025-09-02 |
| Frederic Moll | 男 | Independent Director | 74 | 3.50万美元 | 未持股 | 2025-09-02 |
| Amy Dodrill | 女 | Independent Director | 53 | 未披露 | 未持股 | 2025-09-02 |
| Antal Desai | 男 | Independent Director | 48 | 未披露 | 未持股 | 2025-09-02 |
| Thomas M. Prescott | -- | Chairman of the Board | -- | 未披露 | 未持股 | 2025-09-02 |
| Mary Garrett | -- | Independent Director | -- | 未披露 | 未持股 | 2025-09-02 |
| Elisabeth A. Sandoval Little | -- | Independent Director | -- | 未披露 | 未持股 | 2025-09-02 |
| Larry L. Wood | 男 | Director; President and Chief Executive Officer | 59 | 未披露 | 未持股 | 2025-09-02 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Alaleh Nouri | 女 | Executive Vice President, Chief Legal Officer and Corporate Secretary | 47 | 未披露 | 未持股 | 2025-09-02 |
| Kevin Waters | 男 | Executive Vice President, Principal Accounting Officer and Chief Financial Officer | 49 | 73.50万美元 | 未持股 | 2025-09-02 |
| Hisham Shiblaq | 男 | Executive Vice President and Chief Commercial Officer | 51 | 58.20万美元 | 未持股 | 2025-09-02 |
| Larry L. Wood | 男 | Director; President and Chief Executive Officer | 59 | 未披露 | 未持股 | 2025-09-02 |
董事简历
中英对照 | 中文 | 英文- Taylor Harris
-
Taylor Harris，自2020年12月起担任董事会成员。Harris先生自2018年4月起担任MyoKardia，Inc.的首席财务官，该公司是一家临床阶段的生物制药公司，直至该公司于2020年11月被百时美施贵宝收购。在此之前，Harris先生曾于2016年3月在ZELTIQ Aesthetics, Inc.担任高级副总裁兼首席财务官，该公司是一家营销和许可用于冷冻溶脂程序的设备的公司，直到该公司于2017年4月被Allergan plc.收购。Harris先生自2021年1月起担任HealthCor Catalio Acquisition Company的董事会成员，同时也是该公司审计委员会的成员。Harris先生拥有北卡罗来纳大学教堂山分校的物理学和经济学学士学位。
Taylor Harris has served as a member of board of directors since December 2020. Mr. Harris served as the Chief Financial Officer for MyoKardia, Inc., a clinical-stage biopharmaceutical company, from April 2018 until that company's acquisition by Bristol Myers Squibb in November 2020. Previously, Mr. Harris served as Senior Vice President and Chief Financial Officer of Zeltiq Aesthetics, Inc., a company that markets and licenses devices used for cryolipolysis procedures, from March 2016 until that company's acquisition by Allergan plc. in April 2017. Mr. Harris has served as a member of the board of directors of HealthCor Catalio Acquisition Company, where he is also a member of the audit committee, since January 2021. Mr. Harris holds a B.A. in Physics and Economics from the University of North Carolina at Chapel Hill. - Taylor Harris，自2020年12月起担任董事会成员。Harris先生自2018年4月起担任MyoKardia，Inc.的首席财务官，该公司是一家临床阶段的生物制药公司，直至该公司于2020年11月被百时美施贵宝收购。在此之前，Harris先生曾于2016年3月在ZELTIQ Aesthetics, Inc.担任高级副总裁兼首席财务官，该公司是一家营销和许可用于冷冻溶脂程序的设备的公司，直到该公司于2017年4月被Allergan plc.收购。Harris先生自2021年1月起担任HealthCor Catalio Acquisition Company的董事会成员，同时也是该公司审计委员会的成员。Harris先生拥有北卡罗来纳大学教堂山分校的物理学和经济学学士学位。
- Taylor Harris has served as a member of board of directors since December 2020. Mr. Harris served as the Chief Financial Officer for MyoKardia, Inc., a clinical-stage biopharmaceutical company, from April 2018 until that company's acquisition by Bristol Myers Squibb in November 2020. Previously, Mr. Harris served as Senior Vice President and Chief Financial Officer of Zeltiq Aesthetics, Inc., a company that markets and licenses devices used for cryolipolysis procedures, from March 2016 until that company's acquisition by Allergan plc. in April 2017. Mr. Harris has served as a member of the board of directors of HealthCor Catalio Acquisition Company, where he is also a member of the audit committee, since January 2021. Mr. Harris holds a B.A. in Physics and Economics from the University of North Carolina at Chapel Hill.
- Frederic Moll
-
Frederic Moll自2011年以来一直担任我们的董事会成员。Moll博士自2002年11月以来是Restoration Robotics，Inc.的成员并担任董事会主席。Moll博士也是联合创始人，自2012年9月起担任Auris Health，Inc.的董事长兼首席执行官。Moll博士自2011年以来担任Circuit Therapeutics的领导职务。从2002年到2010年，他曾担任Hansen Medical公司（他也曾共同创立该公司）的首席执行官。在此之前，Moll博士共同创立了直觉外科公司，并从1995年到2002年担任其第一任首席执行官。Moll博士还联合创立了Endo-Therapeutics，Inc.和Origin，后者在被礼来公司（Eli Lilly&Company）收购后成为Guidant Corporation的一家运营公司。Moll博士在Intersectent，Inc.的董事会任职。Moll博士在加州大学伯克利分校（University of California at Berkeley）获得经济学学士学位，在斯坦福大学（Stanford University）获得管理学硕士学位，在华盛顿大学（University of Washington）获得医学博士学位。
Frederic Moll has served as a member of board of directors since August 2011 and has served as Chair since March 2021. Since April 2019 Dr. Moll has served as Chief Development Officer for Johnson & Johnson Medical Devices Companies. Dr. Moll was also a co-founder, and, from September 2012 to 2019 was the Chairman and Chief Executive Officer of Auris Health, Inc. Dr. Moll is also the Founding Partner of Sonder Capital Management, LLC, a healthcare venture capital investment firm. Dr. Moll previously served as member and as Chairman of the board of Restoration Robotics, Inc., from November 2002 until its merger with Venus Concept in November 2019. He has also served on the boards of Shockwave Medical, Inc., since March 2011 where he is a member of the nominating and corporate governance committee, INSIGHTEC Ltd., since June 2020 where he is a member of the audit committee, and Lux Health Tech Acquisition Corp., since June 2020 where he is a member of the audit committee, and he previously served on the board of directors at IntersectENT, Inc. from March 2010 to February 2021 where he was a member of the nominating and corporate governance committee. Dr. Moll received a B.A. in economics from the University of California at Berkeley, an M.S. in management from Stanford University and an M.D. from the University of Washington. - Frederic Moll自2011年以来一直担任我们的董事会成员。Moll博士自2002年11月以来是Restoration Robotics，Inc.的成员并担任董事会主席。Moll博士也是联合创始人，自2012年9月起担任Auris Health，Inc.的董事长兼首席执行官。Moll博士自2011年以来担任Circuit Therapeutics的领导职务。从2002年到2010年，他曾担任Hansen Medical公司（他也曾共同创立该公司）的首席执行官。在此之前，Moll博士共同创立了直觉外科公司，并从1995年到2002年担任其第一任首席执行官。Moll博士还联合创立了Endo-Therapeutics，Inc.和Origin，后者在被礼来公司（Eli Lilly&Company）收购后成为Guidant Corporation的一家运营公司。Moll博士在Intersectent，Inc.的董事会任职。Moll博士在加州大学伯克利分校（University of California at Berkeley）获得经济学学士学位，在斯坦福大学（Stanford University）获得管理学硕士学位，在华盛顿大学（University of Washington）获得医学博士学位。
- Frederic Moll has served as a member of board of directors since August 2011 and has served as Chair since March 2021. Since April 2019 Dr. Moll has served as Chief Development Officer for Johnson & Johnson Medical Devices Companies. Dr. Moll was also a co-founder, and, from September 2012 to 2019 was the Chairman and Chief Executive Officer of Auris Health, Inc. Dr. Moll is also the Founding Partner of Sonder Capital Management, LLC, a healthcare venture capital investment firm. Dr. Moll previously served as member and as Chairman of the board of Restoration Robotics, Inc., from November 2002 until its merger with Venus Concept in November 2019. He has also served on the boards of Shockwave Medical, Inc., since March 2011 where he is a member of the nominating and corporate governance committee, INSIGHTEC Ltd., since June 2020 where he is a member of the audit committee, and Lux Health Tech Acquisition Corp., since June 2020 where he is a member of the audit committee, and he previously served on the board of directors at IntersectENT, Inc. from March 2010 to February 2021 where he was a member of the nominating and corporate governance committee. Dr. Moll received a B.A. in economics from the University of California at Berkeley, an M.S. in management from Stanford University and an M.D. from the University of Washington.
- Amy Dodrill
-
Amy Dodrill当选为高级副总裁兼外科解决方案总裁，自2019年6月起生效。她此前曾担任我们美国外科手术解决方案销售业务的Vice President，在此之前，自2011年10月加入Hillrom以来，她曾担任我们患者支持系统业务的区域Vice President。加入Hillrom公司之前，她曾担任Dynavox Systems公司和GE梦百合公司的多种高级领导职务。
Amy Dodrill, was elected Senior Vice President and President, Surgical Solutions, effective June 2019. She had previously served as Vice President of U.S. Surgical Solutions sales operations and prior to that, as an area vice president in Patient Support Systems business since joining Hillrom in October 2011. Before joining Hillrom, she held several senior leadership roles at DynaVox Systems LLC and GE Healthcare. - Amy Dodrill当选为高级副总裁兼外科解决方案总裁，自2019年6月起生效。她此前曾担任我们美国外科手术解决方案销售业务的Vice President，在此之前，自2011年10月加入Hillrom以来，她曾担任我们患者支持系统业务的区域Vice President。加入Hillrom公司之前，她曾担任Dynavox Systems公司和GE梦百合公司的多种高级领导职务。
- Amy Dodrill, was elected Senior Vice President and President, Surgical Solutions, effective June 2019. She had previously served as Vice President of U.S. Surgical Solutions sales operations and prior to that, as an area vice president in Patient Support Systems business since joining Hillrom in October 2011. Before joining Hillrom, she held several senior leadership roles at DynaVox Systems LLC and GE Healthcare.
- Antal Desai
-
Antal Desai自2015年6月起担任我们的董事会成员。他于2004年9月加入Cardinal Investment Company，Inc.（CPMG，Inc.的前身公司），这是一家投资公司，在全球范围内投资上市和私人公司，如果他目前担任合伙人的话。德赛先生是几家私人公司的董事。德赛在宾夕法尼亚大学沃顿商学院（Wharton School of Pennsylvania）获得经济学学士学位和MBA学位。
Antal Desai has served as a member of board of directors since June 2015. Mr. Desai joined Cardinal Investment Company, Inc. in September 2004 the predecessor firm to CPMG, Inc., an investment firm that invests in publicly-traded and private companies globally, were he currently serves as a Partner. Mr. Desai is a director at several private companies. Mr. Desai received both a B.S. in Economics and an M.B.A. from the Wharton School at the University of Pennsylvania. - Antal Desai自2015年6月起担任我们的董事会成员。他于2004年9月加入Cardinal Investment Company，Inc.（CPMG，Inc.的前身公司），这是一家投资公司，在全球范围内投资上市和私人公司，如果他目前担任合伙人的话。德赛先生是几家私人公司的董事。德赛在宾夕法尼亚大学沃顿商学院（Wharton School of Pennsylvania）获得经济学学士学位和MBA学位。
- Antal Desai has served as a member of board of directors since June 2015. Mr. Desai joined Cardinal Investment Company, Inc. in September 2004 the predecessor firm to CPMG, Inc., an investment firm that invests in publicly-traded and private companies globally, were he currently serves as a Partner. Mr. Desai is a director at several private companies. Mr. Desai received both a B.S. in Economics and an M.B.A. from the Wharton School at the University of Pennsylvania.
- Thomas M. Prescott
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Mary Garrett
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Elisabeth A. Sandoval Little
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Larry L. Wood
-
Larry L. Wood，自2024年4月起担任公司董事会成员。自2007年2月起，Wood先生担任Transcatheter Aortic Valve Replacement公司副总裁，自2023年起，担任外科结构性心脏集团总裁，任职于Edwards Lifesciences Corporation，该公司是结构性心脏病、重症监护和手术监测领域以患者为中心的医疗创新的全球领导者。Wood先生在医疗技术行业拥有40多年的经验，曾在Edwards Lifesciences Corporation和Baxter Healthcare Corporation担任过制造管理、法规事务以及战略和临床营销等职位，主要为外科心脏瓣膜治疗业务服务。Wood先生获得了Pepperdine Graziadio商学院的工商管理硕士学位。
Larry L. Wood,has served as a member of the Company's Board since April 2024. Since February 2007, Mr. Wood has been Corporate Vice President, Transcatheter Aortic Valve Replacement, and since 2023, as Group President for Surgical Structural Heart, at Edwards Lifesciences Corporation, a global leader in patient-focused medical innovations for structural heart disease and critical care and surgical monitoring. Mr. Wood has more than 40 years of experience in the medical technology industry at both Edwards Lifesciences Corporation and Baxter Healthcare Corporation in positions including manufacturing management, regulatory affairs and strategic and clinical marketing, primarily for the surgical heart valve therapy business. Mr. Wood received an M.B.A. from Pepperdine Graziadio Business School. - Larry L. Wood，自2024年4月起担任公司董事会成员。自2007年2月起，Wood先生担任Transcatheter Aortic Valve Replacement公司副总裁，自2023年起，担任外科结构性心脏集团总裁，任职于Edwards Lifesciences Corporation，该公司是结构性心脏病、重症监护和手术监测领域以患者为中心的医疗创新的全球领导者。Wood先生在医疗技术行业拥有40多年的经验，曾在Edwards Lifesciences Corporation和Baxter Healthcare Corporation担任过制造管理、法规事务以及战略和临床营销等职位，主要为外科心脏瓣膜治疗业务服务。Wood先生获得了Pepperdine Graziadio商学院的工商管理硕士学位。
- Larry L. Wood,has served as a member of the Company's Board since April 2024. Since February 2007, Mr. Wood has been Corporate Vice President, Transcatheter Aortic Valve Replacement, and since 2023, as Group President for Surgical Structural Heart, at Edwards Lifesciences Corporation, a global leader in patient-focused medical innovations for structural heart disease and critical care and surgical monitoring. Mr. Wood has more than 40 years of experience in the medical technology industry at both Edwards Lifesciences Corporation and Baxter Healthcare Corporation in positions including manufacturing management, regulatory affairs and strategic and clinical marketing, primarily for the surgical heart valve therapy business. Mr. Wood received an M.B.A. from Pepperdine Graziadio Business School.
高管简历
中英对照 | 中文 | 英文- Alaleh Nouri
Alaleh Nouri，自2018年7月起担任高级副总裁、总法律顾问兼公司秘书。她此前曾于2014年2月至2018年7月在放射肿瘤学公司Accuray Incorporated担任高级副总裁、总法律顾问、公司秘书和首席合规官。Nouri女士获得了U.C. Hastings College of Law的法学博士学位和国际商务商学学士学位，还完成了不列颠哥伦比亚大学金融专业的要求。
Alaleh Nouri has served as SVP, General Counsel & Corporate Secretary since July 2018. She previously served as Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer at Accuray Incorporated, a radiation oncology company, from February 2014 to July 2018. Ms. Nouri received a J.D. from U.C. Hastings College of Law and a Bachelor of Commerce in International Business and also completed the requirements for a Finance specialization from the University of British Columbia.- Alaleh Nouri，自2018年7月起担任高级副总裁、总法律顾问兼公司秘书。她此前曾于2014年2月至2018年7月在放射肿瘤学公司Accuray Incorporated担任高级副总裁、总法律顾问、公司秘书和首席合规官。Nouri女士获得了U.C. Hastings College of Law的法学博士学位和国际商务商学学士学位，还完成了不列颠哥伦比亚大学金融专业的要求。
- Alaleh Nouri has served as SVP, General Counsel & Corporate Secretary since July 2018. She previously served as Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer at Accuray Incorporated, a radiation oncology company, from February 2014 to July 2018. Ms. Nouri received a J.D. from U.C. Hastings College of Law and a Bachelor of Commerce in International Business and also completed the requirements for a Finance specialization from the University of British Columbia.
- Kevin Waters
Kevin Waters，自2018年10月起担任高级副总裁、首席财务官。他此前于2015年9月至2018年10月在放射肿瘤学公司Accuray Incorporated担任首席财务官，并于2013年10月至2015年8月担任财务高级副总裁。沃特斯先生获得工商管理学士学位，在Cal Poly San Luis Obispo获得会计和金融双学位。
Kevin Waters has served as SVP, Chief Financial Officer since October 2018. He previously served as Chief Financial Officer at Accuray Incorporated, a radiation oncology company, from September 2015 to October 2018 and as its SVP, Finance from October 2013 to August 2015. Mr. Waters received a B.S. in Business Administration, with a double concentration in Accounting and Finance from Cal Poly San Luis Obispo.- Kevin Waters，自2018年10月起担任高级副总裁、首席财务官。他此前于2015年9月至2018年10月在放射肿瘤学公司Accuray Incorporated担任首席财务官，并于2013年10月至2015年8月担任财务高级副总裁。沃特斯先生获得工商管理学士学位，在Cal Poly San Luis Obispo获得会计和金融双学位。
- Kevin Waters has served as SVP, Chief Financial Officer since October 2018. He previously served as Chief Financial Officer at Accuray Incorporated, a radiation oncology company, from September 2015 to October 2018 and as its SVP, Finance from October 2013 to August 2015. Mr. Waters received a B.S. in Business Administration, with a double concentration in Accounting and Finance from Cal Poly San Luis Obispo.
- Hisham Shiblaq
Hisham Shiblaq自2019年3月起担任我们的全球商业化副总裁。他此前曾担任Invuity，Inc.（医疗设备公司）的商业运营副总裁（从2017年1月到2019年1月），以及Analogic Corporation的销售副总裁（从2016年6月到2017年1月）。Shiblaq先生获得俄亥俄州立大学心理学学士学位。
Hisham Shiblaq has served as SVP, Global Commercialization since March 2019. He previously served as Vice President of Commercial Operations at Invuity, Inc., a medical device company, from January 2017 to January 2019 and as Vice President of Sales at Analogic Corporation from June 2016 to January 2017. Mr. Shiblaq received a B.A. in Psychology from Ohio State University.- Hisham Shiblaq自2019年3月起担任我们的全球商业化副总裁。他此前曾担任Invuity，Inc.（医疗设备公司）的商业运营副总裁（从2017年1月到2019年1月），以及Analogic Corporation的销售副总裁（从2016年6月到2017年1月）。Shiblaq先生获得俄亥俄州立大学心理学学士学位。
- Hisham Shiblaq has served as SVP, Global Commercialization since March 2019. He previously served as Vice President of Commercial Operations at Invuity, Inc., a medical device company, from January 2017 to January 2019 and as Vice President of Sales at Analogic Corporation from June 2016 to January 2017. Mr. Shiblaq received a B.A. in Psychology from Ohio State University.
- Larry L. Wood
Larry L. Wood，自2024年4月起担任公司董事会成员。自2007年2月起，Wood先生担任Transcatheter Aortic Valve Replacement公司副总裁，自2023年起，担任外科结构性心脏集团总裁，任职于Edwards Lifesciences Corporation，该公司是结构性心脏病、重症监护和手术监测领域以患者为中心的医疗创新的全球领导者。Wood先生在医疗技术行业拥有40多年的经验，曾在Edwards Lifesciences Corporation和Baxter Healthcare Corporation担任过制造管理、法规事务以及战略和临床营销等职位，主要为外科心脏瓣膜治疗业务服务。Wood先生获得了Pepperdine Graziadio商学院的工商管理硕士学位。
Larry L. Wood,has served as a member of the Company's Board since April 2024. Since February 2007, Mr. Wood has been Corporate Vice President, Transcatheter Aortic Valve Replacement, and since 2023, as Group President for Surgical Structural Heart, at Edwards Lifesciences Corporation, a global leader in patient-focused medical innovations for structural heart disease and critical care and surgical monitoring. Mr. Wood has more than 40 years of experience in the medical technology industry at both Edwards Lifesciences Corporation and Baxter Healthcare Corporation in positions including manufacturing management, regulatory affairs and strategic and clinical marketing, primarily for the surgical heart valve therapy business. Mr. Wood received an M.B.A. from Pepperdine Graziadio Business School.- Larry L. Wood，自2024年4月起担任公司董事会成员。自2007年2月起，Wood先生担任Transcatheter Aortic Valve Replacement公司副总裁，自2023年起，担任外科结构性心脏集团总裁，任职于Edwards Lifesciences Corporation，该公司是结构性心脏病、重症监护和手术监测领域以患者为中心的医疗创新的全球领导者。Wood先生在医疗技术行业拥有40多年的经验，曾在Edwards Lifesciences Corporation和Baxter Healthcare Corporation担任过制造管理、法规事务以及战略和临床营销等职位，主要为外科心脏瓣膜治疗业务服务。Wood先生获得了Pepperdine Graziadio商学院的工商管理硕士学位。
- Larry L. Wood,has served as a member of the Company's Board since April 2024. Since February 2007, Mr. Wood has been Corporate Vice President, Transcatheter Aortic Valve Replacement, and since 2023, as Group President for Surgical Structural Heart, at Edwards Lifesciences Corporation, a global leader in patient-focused medical innovations for structural heart disease and critical care and surgical monitoring. Mr. Wood has more than 40 years of experience in the medical technology industry at both Edwards Lifesciences Corporation and Baxter Healthcare Corporation in positions including manufacturing management, regulatory affairs and strategic and clinical marketing, primarily for the surgical heart valve therapy business. Mr. Wood received an M.B.A. from Pepperdine Graziadio Business School.